Seer, Inc. (NASDAQ: SEER) is a life sciences company focused on next-generation proteomics, offering a platform that enables comprehensive, high-throughput analysis of proteins at scale. Founded in 2016 and headquartered in South San Francisco, Seer’s mission is to transform biomarker discovery and therapeutic development by revealing unprecedented proteome-level insights. The company’s proprietary technology integrates nanoparticle-based sample preparation with advanced mass spectrometry workflows, delivering deep proteome coverage across diverse biological samples.
The centerpiece of Seer’s offering is the Proteograph Product Suite, which combines magnetic nanoparticle reagents, automated sample processing, and data analysis software to streamline proteomics studies. This end-to-end solution supports large-scale experiments in pharmaceutical and biotechnology research, enabling clients to identify and quantify thousands of proteins in plasma, serum, and other complex matrices. By reducing hands-on time and enhancing reproducibility, the Proteograph Suite accelerates discovery and validation of novel biomarkers and therapeutic targets.
Seer’s platform has been adopted by leading academic institutions, contract research organizations, and biopharmaceutical companies across North America, Europe, and Asia. The company maintains a global network of distribution partners and provides technical support for deployment and method optimization. Strategic collaborations with mass spectrometry instrument manufacturers and bioinformatics firms further extend Seer’s reach and integration into existing proteomics workflows, fostering a growing community of users advancing precision medicine research.
Led by a management team with deep expertise in life-science instrumentation, proteomics, and computational analysis, Seer continues to expand its technological capabilities and application portfolio. With a strong foundation in nanoparticle chemistry and systems engineering, the company is well-positioned to address emerging needs in personalized healthcare and translational research. Seer’s ongoing innovation aims to unlock new dimensions of the proteome, paving the way for improved diagnostics and targeted therapies.
AI Generated. May Contain Errors.